<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446912</url>
  </required_header>
  <id_info>
    <org_study_id>D3461C00005</org_study_id>
    <nct_id>NCT02446912</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment
      regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to
      severely active, autoantibody-positive systemic lupus erythematosus (SLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled
      study to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of
      anifrolumab versus placebo in subjects with moderately to severely active,
      autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care
      (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2015</start_date>
  <completion_date type="Actual">July 17, 2018</completion_date>
  <primary_completion_date type="Actual">July 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)</measure>
    <time_frame>Week 52</time_frame>
    <description>Maintained OCS reduction was defined by meeting all the following criteria:
Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)</measure>
    <time_frame>Week 12</time_frame>
    <description>50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria:
Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)</measure>
    <time_frame>Week 24</time_frame>
    <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Flare Rate</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)</measure>
    <time_frame>Week 52</time_frame>
    <description>A BICLA responder was achieved if all of the following criteria was met:
All criteria related to SRI(4) (please see primary endpoint) plus:
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Adverse Events (AE)</measure>
    <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
    <description>An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death).
AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Vital Signs</measure>
    <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
    <description>Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.
Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Physical Examinations</measure>
    <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
    <description>Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported.
Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index</measure>
    <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
    <description>The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories.
Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Laboratory Tests</measure>
    <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
    <description>Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered &quot;yes&quot; at any time during the treatment period (Baseline to Week 52) to one of the 10 categories:
Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Active Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Anifrolumab - higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anifrolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anifrolumab - lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anifrolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anifrolumab</intervention_name>
    <description>Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses</description>
    <arm_group_label>Anifrolumab - higher dose</arm_group_label>
    <arm_group_label>Anifrolumab - lower dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV administration every 4 weeks from Week 0 to Week 48</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 through 70 years at the time of screening

          2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982
             revised criteria ≥24 weeks prior to signing the Informed Consent form (ICF)

          3. Currently receiving at least 1 of the following:

               1. Where prednisone is the single standard of care medication (ie, the subject is
                  not concurrently receiving any medication listed in inclusion criterion 3(c)), a
                  dose of oral prednisone ≥7.5 mg/day but ≤40 mg/day (or prednisone equivalent) for
                  a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or
                  prednisone equivalent the subject is taking must be stable for a minimum of 2
                  weeks prior to randomisation.

               2. Where prednisone is not the single standard of care medication (ie, the subject
                  is concurrently receiving at least one medication listed in inclusion criterion
                  3(c)), a dose of oral prednisone (≤40 mg/day) (or prednisone equivalent) for a
                  minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral
                  prednisone or prednisone equivalent the subject is taking must be stable for a
                  minimum of 2 weeks prior to randomisation.

               3. Any of the following medications administered for a minimum of 12 weeks prior to
                  signing the informed consent, and at a stable dose for a minimum of 8 weeks prior
                  to signing the informed consent through Day 1:

             (i) Azathioprine ≤200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine,
             quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv)
             Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150
             mg/day

          4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at
             least 1 of which must be:

               1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay
                  (IFA) at the central laboratory with titre ≥1:80; OR

               2. Anti-dsDNA antibodies at screening elevated to above normal (including
                  indeterminante), as per the central laboratory; OR

               3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the
                  central laboratory.

          5. At Screening, Disease Activity Adjudication Group confirmation of:

             SLEDAI-2K Criteria: SLEDAI-2K score ≥6 points and &quot;Clinical&quot; SLEDAI-2K score ≥4
             points. The &quot;Clinical&quot; SLEDAI-2K is the SLEDAI-2K assessment score without the
             inclusion of points attributable to any urine or laboratory results including
             immunologic measures.

          6. Must not have active or latent TB on either chest radiograph or by quantiferon gold
             test

          7. Day 1 &quot;Clinical&quot; SLEDAI-2K score ≥4 points

          8. OCS dose stable for at least 2 weeks prior to randomisation

          9. Stable SLE SOC treatment at the time of randomisation

         10. Women of child-bearing potential must have a negative serum β-hCG test and negative
             urine pregnancy test at randomisation (Day 1) prior to administration of
             investigational product

        Exclusion Criteria:

          1. Receipt of any investigational product (small molecule or biologic agent) within 4
             weeks or 5 half-lives prior to signing of the ICF, whichever is greater

          2. Receipt of any of the following:

             (a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to
             Day 1

          3. History of, or current diagnosis of, a clinically significant non SLE-related
             vasculitis syndrome.

          4. Active severe or unstable neuropsychiatric SLE

          5. Active severe SLE-driven renal disease

          6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any
             history of overlap syndromes of SLE or SSc.

          7. History of, or current, inflammatory joint or skin disease other than SLE

          8. History of any non-SLE disease that has required treatment with oral or parenteral
             corticosteroids for more than 2 weeks within the last 24 weeks prior to signing the
             ICF

          9. Known history of a primary immunodeficiency, splenectomy, or any underlying condition
             that predisposes the subject to infection, or a positive result for human
             immunodeficiency virus (HIV) infection confirmed by central laboratory at screening.
             Subjects refusing HIV testing during the screening period will not be eligible for
             study participation

         10. Confirmed positive test for hepatitis B or hepatitis C

         11. Any severe herpes infection at any time prior to Week 0 (Day 1)

         12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial
             treatment within 3 years prior to randomization

         13. History of cancer, apart from:

               1. Squamous or basal cell carcinoma of the skin that has been successfully treated

               2. Cervical cancer in situ that has been successfully treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Hutman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Science Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>91942-3191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004AUL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juiz de Fora</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90560-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osorno</city>
        <zip>5311092</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8320000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vina del Mar</city>
        <zip>2520997</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Armenia</city>
        <zip>630004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dessau-RoBlau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirchheim</city>
        <zip>73230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9122001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>49281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arequipa</city>
        <zip>54</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15023</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15033</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15073</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-297</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sosnowiec</city>
        <zip>41-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Starachowice</city>
        <zip>27-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ustron</city>
        <zip>43-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>010584</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tg Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung Hsien</city>
        <zip>83342</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE1 2PR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Romford</city>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staffordshire</city>
        <zip>WS11 5XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3461C00005&amp;amp;attachmentIdentifier=dbb257f6-3341-4f6e-87e5-8cef8eb24694&amp;amp;fileName=2019Mar06_D3461C00005_(TULIP)_18May2016_Protocol_Redaction_V2.0_Final.pdf&amp;amp;versionIdentifier=</url>
    <description>CSP redacted.</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D3461C00005&amp;amp;attachmentIdentifier=fbbb0a3a-88f7-446c-81fe-9e642be982ce&amp;amp;fileName=2019Mar11_D3461C00005_(TULIP)__SAP_Final_Redaction_V2.0_Final.pdf&amp;amp;versionIdentifier=</url>
    <description>SAP redacted.</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>November 18, 2019</results_first_submitted>
  <results_first_submitted_qc>November 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2019</results_first_posted>
  <disposition_first_submitted>May 31, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 7, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 10, 2019</disposition_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Active Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02446912/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02446912/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the trial at 123 sites in 18 countries worldwide.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Anifrolumab 150 mg</title>
          <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="P2">
          <title>Anifrolumab 300 mg</title>
          <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Who Completed Week 52</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition under investigation worsened</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>Anifrolumab 150 mg</title>
          <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="B2">
          <title>Anifrolumab 300 mg</title>
          <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="184"/>
            <count group_id="B4" value="457"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="12.05"/>
                    <measurement group_id="B2" value="42.0" spread="11.99"/>
                    <measurement group_id="B3" value="41.0" spread="12.30"/>
                    <measurement group_id="B4" value="41.3" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 18</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 18 to &lt; 65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="437"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.02" spread="8.208"/>
                    <measurement group_id="B2" value="162.99" spread="7.829"/>
                    <measurement group_id="B3" value="163.10" spread="8.030"/>
                    <measurement group_id="B4" value="163.24" spread="7.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.57" spread="19.469"/>
                    <measurement group_id="B2" value="75.36" spread="20.343"/>
                    <measurement group_id="B3" value="74.69" spread="19.332"/>
                    <measurement group_id="B4" value="74.72" spread="19.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.31" spread="6.81"/>
                    <measurement group_id="B2" value="28.25" spread="6.899"/>
                    <measurement group_id="B3" value="28.09" spread="7.145"/>
                    <measurement group_id="B4" value="28.00" spread="6.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)</title>
        <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)</title>
          <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) No new organ systems affected, defined by 1 or more British Isles Lupus Assessment Group (BILAG-2004) A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.412</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.7</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
        <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
          <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.455</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>17.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)</title>
        <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
        <time_frame>Week 52</time_frame>
        <population>All participants who received investigational product with non-missing baseline measurements, and high IFN test results.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)</title>
          <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
          <population>All participants who received investigational product with non-missing baseline measurements, and high IFN test results.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.549</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.4</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Who Achieved an Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
        <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
        <time_frame>Week 52</time_frame>
        <population>All participants who received investigational product with non-missing baseline measurements, and high IFN test results.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved an Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
          <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
          <population>All participants who received investigational product with non-missing baseline measurements, and high IFN test results.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.261</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>17.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)</title>
        <description>Maintained OCS reduction was defined by meeting all the following criteria:
Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
        <time_frame>Week 52</time_frame>
        <population>All participants who received investigational product, who had a baseline OCS ≥10 mg/day, and had non-missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)</title>
          <description>Maintained OCS reduction was defined by meeting all the following criteria:
Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold.</description>
          <population>All participants who received investigational product, who had a baseline OCS ≥10 mg/day, and had non-missing baseline measurements.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.180</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>21.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
        <description>Maintained OCS reduction was defined by meeting all of the following criteria:
Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
        <time_frame>Week 52</time_frame>
        <population>All participants who received investigational product, who had a baseline OCS ≥10 mg/day, and had non-missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
          <description>Maintained OCS reduction was defined by meeting all of the following criteria:
Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
          <population>All participants who received investigational product, who had a baseline OCS ≥10 mg/day, and had non-missing baseline measurements.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.013</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)</title>
        <description>50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria:
Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants who received investigational product, had a baseline CLASI Activity Score ≥10, and had non-missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)</title>
          <description>50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all of the following criteria:
Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the pre-specified analysis threshold before assessment.</description>
          <population>All participants who received investigational product, had a baseline CLASI Activity Score ≥10, and had non-missing baseline measurements.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.054</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>34.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
        <description>50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all the following criteria:
Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants who received investigational product, had a baseline CLASI Activity Score ≥10, and had non-missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
          <description>50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline was defined by meeting all the following criteria:
Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medication confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
          <population>All participants who received investigational product, had a baseline CLASI Activity Score ≥10, and had non-missing baseline measurements.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.034</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>36.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)</title>
        <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold.</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)</title>
          <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in participants lupus disease activity. Worsening was defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the pre-specified threshold.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.905</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
        <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
        <time_frame>Week 24</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
          <description>SRI(4) was defined as meeting all of the following criteria:
Reduction from baseline of ≥4 points in the SLEDAI-2K No new organ systems affected, defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items No worsening from baseline in lupus disease activity. Worsening defined as an increase of ≥0.30 points on a 3-point PGA VAS No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc allowed threshold.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <p_value>0.515</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Flare Rate</title>
        <description>A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received investigational product with non-missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Flare Rate</title>
          <description>A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.</description>
          <population>Full analysis set - all randomized participants who received investigational product with non-missing baseline measurements.</population>
          <units>Annualized flare rate ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62"/>
                    <measurement group_id="O2" value="0.60"/>
                    <measurement group_id="O3" value="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysed using a negative binomial regression model. The response variable in the model is the number of flares over the 52-week treatment period. The model includes covariates of treatment group, and the stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;=10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]). The logarithm of the follow-up time is used as an offset variable.</non_inferiority_desc>
            <p_value>0.258</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)</title>
        <description>A BICLA responder was achieved if all of the following criteria was met:
All criteria related to SRI(4) (please see primary endpoint) plus:
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)</title>
          <description>A BICLA responder was achieved if all of the following criteria was met:
All criteria related to SRI(4) (please see primary endpoint) plus:
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>19.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
        <description>A BICLA responder was achieved if all of the following criteria was met:
All criteria related to SRI(4) (please see primary endpoint) plus:
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigation product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Post-Hoc Analysis With Revised Restricted Medication Rules)</title>
          <description>A BICLA responder was achieved if all of the following criteria was met:
All criteria related to SRI(4) (please see primary endpoint) plus:
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by 1 or more BILAG-2004 A or 1 or more new BILAG-2004 B item No discontinuation of investigational product and no use of restricted medications beyond the revised post-hoc analysis threshold before assessment.
Revised rules were designed to be more clinically appropriate, capture intent of protocol, minimize the risk of restricted medications confounding efficacy, and to allow appropriate quantification and interpretation of the relevant endpoints.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigation product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The difference in estimates and associated 95% CI are weighted and are calculated using a stratified Cochran-Mantel-Haenszel (CMH) approach, with stratification factors (SLEDAI-2K score at screening [&lt;10 points vs &gt;= 10 points], Week 0 OCS dose [&lt;10 mg/day vs &gt;=10 mg/day prednisone or equivalent] and type I IFN gene signature test result at screening [high vs low]).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.7</ci_lower_limit>
            <ci_upper_limit>26.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Adverse Events (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.</description>
        <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Adverse Events (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)</title>
        <description>An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death).
AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
        <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)</title>
          <description>An AESI is an AE of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by the Investigator to the Sponsor/Sponsor's delegate. An AESI may be serious or nonserious. The events of interest are serious infections, including non opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, TB (including latent TB), influenza, vasculitis (non-SLE), and MACE (including stroke, MI, or cardiovascular death).
AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Vital Signs</title>
        <description>Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.
Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
        <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Vital Signs</title>
          <description>Vital signs included oral temperature, blood pressure (BP), pulse rate, and respiratory rate.
Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Physical Examinations</title>
        <description>Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported.
Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
        <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Physical Examinations</title>
          <description>Physical examinations included height and weight. Participants were weighed at each study visit and any medically significant changes were reported.
Physical examination values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores</title>
        <description>ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores</title>
          <description>ECGs documented the date, time, heart rate, QRS duration, PR interval, RR interval, QT, and corrected QT interval, which were calculated using the Fridericia formula. The investigator judged the overall interpretation as normal or abnormal, and if abnormal it was decided as to whether or not the abnormality was clinically significant or not clinically significant.</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index</title>
        <description>The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories.
Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
        <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index</title>
          <description>The modified SELENA flare index was completed by the Investigator or delegated/qualified physician. Assessment of flares were scored in comparison to the participant's previous visit and should only include findings which, in the opinion of the Investigator, are due to systemic lupus erythematosus (SLE) disease activity within that timeframe. Flare was defined as any 1 criterion present in either the Mild/Moderate Flare or Severe Flare categories.
Number of flares were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Laboratory Tests</title>
        <description>Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
        <time_frame>Baseline to End of Trial (Maximum of 60 weeks)</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Laboratory Tests</title>
          <description>Laboratory tests were collected at central clinical laboratories and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose [Week 48]), or until Week 52 for participants who enrolled onto the long term extension (LTE).</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
        <description>The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered &quot;yes&quot; at any time during the treatment period (Baseline to Week 52) to one of the 10 categories:
Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
          <description>The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior was defined as the number of participants who answered &quot;yes&quot; at any time during the treatment period (Baseline to Week 52) to one of the 10 categories:
Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide</description>
          <population>Full analysis set - all randomized participants who received at least one dose of investigational product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score</title>
        <description>PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>All participants who received study drug with non-missing baseline and week 52 measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 150 mg</title>
            <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg</title>
            <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score</title>
          <description>PHQ-8 is a 8-item self-report scale, all items are rated on a score of 0-3, for a total range of 0-24. PHQ-8 assesses symptoms of depression over the previous 2 weeks. Higher scores indicate more depressive symptoms. A negative change from baseline score indicates improvement in symptoms.</description>
          <population>All participants who received study drug with non-missing baseline and week 52 measurements.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="4.43"/>
                    <measurement group_id="O2" value="-2.7" spread="5.58"/>
                    <measurement group_id="O3" value="-1.7" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to End of Trial (Maximum of 60 weeks post first dose)</time_frame>
      <desc>AEs were either spontaneously reported by the participant or reported in response to open questions, revealed by observation, or were changes from baseline/deterioration in tests and vital signs that met SAE criteria or led to IP discontinuation. Full analysis set: All participants who had received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anifrolumab 150 mg</title>
          <description>Anifrolumab (150 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="E2">
          <title>Anifrolumab 300 mg</title>
          <description>Anifrolumab (300 mg) administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebo administered via an intravenous infusion (IV) every 4 weeks for up to 48 weeks (13 doses)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Appenicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Neuropsychiatric lupus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="180"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Steroid withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E2" events="58" subjects_affected="36" subjects_at_risk="180"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="93"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E3" events="27" subjects_affected="19" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E2" events="37" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E3" events="32" subjects_affected="13" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" events="37" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E3" events="23" subjects_affected="18" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Leader</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>+46317761000</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

